MICHAEL PERRAUT: Open Payments
NPI 1013042209 · CALIFORNIA, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$450 in 31 payments from 9 companies in 2025. Trend: 2023 $424 · 2024 $515 · 2025 $450
Food & beverage: $450
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 20 | $218 |
| Lilly USA, LLC | 3 | $58 |
| Novo Nordisk Inc | 2 | $51 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Tactile Systems Technology Inc | 1 | $23 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $21 |
| PFIZER INC. | 1 | $20 |
| AstraZeneca Pharmaceuticals LP | 1 | $18 |
| Exact Sciences Corporation | 1 | $17 |
Products named: QULIPTA, UBRELVY, MOUNJARO, VRAYLAR, Rybelsus, GEMTESA, Flexitouch Plus, JOURNAVX.
Industry payments across MD — which companies pay providers there.
